American Association for Cancer Research News
FASgen, Inc. Presents Ovarian Cancer Efficacy and Toxicology Data to the American Association for Cancer Research
FAS31 inhibits fatty acid synthesis in SKOV3 human ovarian cancer cells in vitro (IC-50 = 6.09 +/- 0.4 ug/ml) at a concentration similar to induce cytotoxicity (LC-50 = 5.2 +/- 2.0 ug/ml). FAS 31 (50 mg/kg/day) for 2 weeks substantially inhibited SKOV3 xenograft growth by >90% compared to vehicle. FAS activity in the treated tumor xenografts was reduced by 82%. This is consistent with published in vitro studies where inhibition of FAS pathway activity by at least 20% led to brisk apoptosis in human cancer cells. No gross or microscopic organ toxicity was identified.
In maximally tolerated dose studies, male and female rats were challenged with increasing single doses of FAS 31 ranging from 0 (vehicle) to 1000 mg/Kg ip or po and followed for 8 days. Aside from one death in the female rats treated with 1000 mg/Kg (ip), no overt toxicity was noted in any other animals; normal motor activity was recorded. In a five-day rat toxicology study, male and female rats were challenged with twice-daily doses of FAS 31 from 0 to 500 mg/Kg ip or orally. No abnormal behavior or distress was noted attributable to FAS 31. All chemistry and hematology studies were within normal limits.
The multiple successful mouse efficacy trials in human ovarian cancer cell lines, showing 80% reduction in SKOV-3 tumor xenografts, and the combination of toxicity, maximum tolerated dose, bioavailability and pK studies lead to the conclusions that FAS31 is efficacious against ovarian cancer tumors, is non-toxic and is a viable pharmacological candidate for anti-cancer therapy.
About FASgen, Inc.: FASgen, Inc. is a drug development company founded in 2000 by four distinguished
The Company have has designed and synthesized many compounds that selectively inhibit fatty acid biosynthesis. One group of these compounds holds great promise for new highly specific therapeutics for cancer and the lead compound, FAS31, has demonstrated remarkable efficacy in the reduction in size of tumors in eight different xenograft models, and is in final preparation for starting clinical trials. Additional compounds have the potential of specific therapeutics for obesity and related metabolic disorder. A final group of compounds have the potential of specific therapeutics for TB, including multiple drug resistant TB (MDR-TB) and latent TB infections that
affect one third of the world's population. For more information, visit FASgen's website at www.fasgen.com
SOURCE FASgen, Inc.
Search Our News Using Google Search
Can't find what you want? Try using Google:
